Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The United Arab Emirates-based investment group is a prominent sovereign or private investment entity currently partnering with BioHarvest Sciences on high-value botanical synthesis projects. On March 31, 2026, the group was identified as the primary partner in a breakthrough development program that successfully created the first stable cell culture for a rare and endangered fragrance-producing plant. This partnership utilizes BioHarvest's proprietary Botanical Synthesis technology to produce complex fragrance molecules, such as sesquiterpenes and chromones, at industrial scale without harvesting original plants. The group operates under a strict non-disclosure agreement (NDA) regarding its specific identity and the exact plant species being targeted, which is widely regarded as one of the world's most valuable fragrance raw materials. The investment group's involvement highlights a strategic focus on sustainable, high-tech production of luxury ingredients for the global fragrance and wellness markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on United Arab Emirates-based investment group.